CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 199 enrolled
Drug / intervention
Etripamil +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02296190
NCT02296190Phase 2Completed
CompareCT.gov

Multi-Center, Placebo-Controlled, Dose-Ranging Phase 2 Electrophysiological Study of Intranasal Administration of MSP-2017 for the Conversion of Induced Paroxysmal Supraventricular Tachycardia (PSVT) to Sinus Rhythm

Milestone Pharmaceuticals Inc.·interventional·Posted Nov 20, 2014·Updated Dec 30, 2020

In Brief

A Phase 2 clinical trial evaluating Etripamil and Placebo for Paroxysmal Supraventricular Tachycardia (PSVT). Completed, enrolled 199 participants across 30 sites in 2 countries.

Detailed Summary

The primary objective of this study is to demonstrate the superiority of at least 1 dose of intranasal (IN) MSP-2017 (Etripamil) over placebo in terminating PSVT induced in an electrophysiology (EP) laboratory.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParoxysmal Supraventricular Tachycardia (PSVT)
CountriesCanada, United States
CollaboratorsMedpace, Inc.

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedNov 20, 2014
Enrollment StartMar 27, 2015
Primary CompletionDec 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 11.6 years ago

Interventions

Etripamildrug

intranasal administration via 4 prefilled Aptar Pharma Unit-Dose Spray devices

Placebodrug

intranasal administration via 4 prefilled Aptar Pharma Unit-Dose Spray devices